Background/Objectives: Idiopathic pulmonary fibrosis (IPF) registries are established to enhance understanding of its natural history. Methods: Serbia (RS) participated in the EMPIRE (European Multi-Partner IPF Registry) from June 2015 to October 2022, involving four centers. The registry included patients over 18 diagnosed with IPF based on the 2011 international criteria. We aimed to gather key clinical, functional, and survival data, along with treatment information for IPF patients in RS, using a centralized electronic case report for consistency. Results: 188 RS patients participated (median age at diagnosis 65, 63.8% male, 51% smoking history, 56% radiological usual interstitial pneumonia (UIP) pattern). At the diagnosis, median forced vital capacity (FVC) was 73.7% and diffusion capacity for carbon monoxide (DLCO) was 38%. At initiation of antifibrotic therapy, median FVC was 73.2% (71.5% for deceased, 75.8% for survivors (p = 0.455), and DLCO was 33.8% (19.9% for deceased, and 35.6% for survivors (p = 0.046)). The median long-term survival from diagnosis was 29.4 months (95% CI: 22.6-36.2 months), and 9.4 months (95% CI: 5.9-12.9 months) from the initiation of therapy, with no difference in the duration of antifibrotic treatment between survivors and deceased (p = 0.598). Conclusions: The RS EMPIRE cohort represents a younger, less comorbid population with fewer smokers and more probable UIP, factors linked to a favorable prognosis. Nevertheless, survival was poorer than expected, mainly due to advanced disease severity at the time of antifibrotic initiation, as indicated by lower DLCO. These findings highlight the importance of earlier diagnosis and treatment before significant physiological decline to improve outcomes.

Center for Radiology University Clinical Center of Serbia 11000 Belgrade Serbia

Clinic for Allergology and Immunology University Clinical Center of Serbia 11000 Belgrade Serbia

Clinic for Pulmonology University Clinical Center of Kragujevac 34000 Kragujevac Serbia

Clinic for Pulmonology University Clinical Center of Nis 18000 Nis Serbia

Clinic for Pulmonology University Clinical Center of Serbia 11000 Belgrade Serbia

Department of Respiratory Medicine Thomayer University Hospital 1st Faculty of Medicine Charles University Prague 12108 Prague Czech Republic

Faculty of Medicine University of Belgrade 11000 Belgrade Serbia

Faculty of Medicine University of Nis 18000 Nis Serbia

Faculty of Medicine University of Novi Sad 21000 Novi Sad Serbia

Institute for Pulmonary Diseases of Vojvodina 21000 Novi Sad Serbia

Zobrazit více v PubMed

Raghu G., Remy-Jardin M., Richeldi L., Thomson C.C., Inoue Y., Johkoh T., Kreuter M., Lynch D.A., Maher T.M., Martinez F.J., et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022;205:e18–e47. doi: 10.1164/rccm.202202-0399ST. PubMed DOI PMC

Monteleone G., ILDs Study Group Sip/IRS. Bergantini L., D’Alessandro M., Pianigiani T., Simonetti J., Iovene B., Varone F., Sgalla G., Richeldi L., et al. The management of Familial Pulmonary Fibrosis in different medical settings: Where does that leave us? An Italian na-tionwide survey. Sarcoidosis Vasc. Diffus. Lung Dis. 2024;41:e2024047. doi: 10.36141/svdld.v41i3.15744. PubMed DOI PMC

Saha P., Talwar P. Idiopathic pulmonary fibrosis (IPF): Disease pathophysiology, targets, and potential therapeutic interventions. Mol. Cell. Biochem. 2024;479:2181–2194. doi: 10.1007/s11010-023-04845-6. PubMed DOI

Shakeel I., Afzal M., Islam A., Sohal S.S., Hassan M.I. Idiopathic pulmonary fibrosis: Pathophysiology, cellular signaling, diagnostic and therapeutic approaches. Med. Drug Discov. 2023;20:100167. doi: 10.1016/j.medidd.2023.100167. DOI

Blokland K.E.C., Waters D.W., Schuliga M., Read J., Pouwels S.D., Grainge C.L., Jaffar J., Westall G., Mutsaers S.E., Prêle C.M., et al. Senescence of IPF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing. Pharmaceutics. 2020;12:389. doi: 10.3390/pharmaceutics12040389. PubMed DOI PMC

Wisman M., Nizamoglu M., Noordhoek J.A., Timens W., Burgess J.K., Heijink I.H. Dysregulated cross-talk between alveolar epithelial cells and stromal cells in idiopathic pulmonary fibrosis reduces epithelial regenerative capacity. Front. Med. 2023;10:1182368. doi: 10.3389/fmed.2023.1182368. PubMed DOI PMC

Jin C., Chen Y., Wang Y., Li J., Liang J., Zheng S., Zhang L., Li Q., Wang Y., Ling F., et al. Single-cell RNA sequencing reveals special basal cells and fibroblasts in idiopathic pulmonary fibrosis. Sci. Rep. 2024;14:15778. doi: 10.1038/s41598-024-66947-5. PubMed DOI PMC

Tzilas V., Koti A., Papandrinopoulou D., Tsoukalas G. Prognostic factors in idiopathic pulmonary fibrosis. Am. J. Med. Sci. 2009;338:481–485. doi: 10.1097/MAJ.0b013e3181ad5984. PubMed DOI

Ley B., Collard H.R., King T.E. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2011;183:431–440. doi: 10.1164/rccm.201006-0894CI. PubMed DOI

King T.E., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Glaspole I., Glassberg M.K., Gorina E., Hopkins P.M., Kardatzke D., Lancaster L., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014;370:2083–2092. doi: 10.1056/NEJMoa1402582. PubMed DOI

Finnerty J.P., Ponnuswamy A., Dutta P., Abdelaziz A., Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: A systematic review and meta-analysis. BMC Pulm. Med. 2021;21:411. doi: 10.1186/s12890-021-01783-1. PubMed DOI PMC

Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.-F., Flaherty K.R., Lasky J.A., et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL. PubMed DOI PMC

Graham B.L., Brusasco V., Burgos F., Cooper B.G., Jensen R., Kendrick A., MacIntyre N.R., Thompson B.R., Wanger J. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 2017;49:1600016. doi: 10.1183/13993003.00016-2016. PubMed DOI

Graham B.L., Steenbruggen I., Miller M.R., Barjaktarevic I.Z., Cooper B.G., Hall G.L., Hallstrand T.S., Kaminsky D.A., McCarthy K., McCormack M.C., et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am. J. Respir. Crit. Care Med. 2019;200:e70–e88. doi: 10.1164/rccm.201908-1590ST. PubMed DOI PMC

ATS Statement. Guidelines for the Six-Minute Walk Test. Am. J. Respir. Crit. Care Med. 2002;166:111–117. doi: 10.1164/ajrccm.166.1.at1102. PubMed DOI

Kolonics-Farkas A.M., Šterclová M., Mogulkoc N., Lewandowska K., Müller V., Hájková M., Kramer M., Jovanovic D., Tekavec-Trkanjec J., Studnicka M., et al. Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries. Front. Med. 2021;8:729203. doi: 10.3389/fmed.2021.729203. PubMed DOI PMC

Jo H.E., Glaspole I., Grainge C., Goh N., Hopkins P.M.A., Moodley Y., Reynolds P.N., Chapman S., Walters E.H., Zappala C., et al. Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur. Respir. J. 2017;49:1601592. doi: 10.1183/13993003.01592-2016. PubMed DOI

Tran T., Šterclová M., Mogulkoc N., Lewandowska K., Müller V., Hájková M., Kramer M.R., Jovanović D., Tekavec-Trkanjec J., Studnicka M., et al. The European MultiPartner IPF registry (EMPIRE): Validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respir. Res. 2020;21:11. doi: 10.1186/s12931-019-1271-z. PubMed DOI PMC

Behr J., Prasse A., Wirtz H., Koschel D., Pittrow D., Held M., Klotsche J., Andreas S., Claussen M., Grohé C., et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: Long-term results of the INSIGHTS-IPF registry. Eur. Respir. J. 2020;56:1902279. doi: 10.1183/13993003.02279-2019. PubMed DOI

Kaunisto J., Salomaa E.-R., Hodgson U., Kaarteenaho R., Kankaanranta H., Koli K., Vahlberg T., Myllärniemi M. Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry. ERJ Open Res. 2019;5:00170-2018. doi: 10.1183/23120541.00170-2018. PubMed DOI PMC

Gao J., Kalafatis D., Carlson L., Pesonen I.H.A., Li C.-X., Wheelock Å., Magnusson J.M., Sköld C.M. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: A longitudinal analysis of the Swedish IPF Registry. Respir. Res. 2021;22:40. doi: 10.1186/s12931-021-01634-x. PubMed DOI PMC

Culver D., Yow E., Neely M., Belperio J., Bender S., Andrade J.D., Roman J., Whelan T., Palmer S., Conoscenti C. Characteristics of patients with idiopathic pulmonary fibrosis (ipf) in the us: Data from the ipf-pro registry. CHEST. 2018;154:397A–398A. doi: 10.1016/j.chest.2018.08.366. DOI

Vasakova M., Sterclova M., Mogulkoc N., Kus J., Müller V., Hajkova M., Jovanovic D., Tekavec-Trkanjec J., Kremer M., Svoboda M., et al. Real world idiopathic pulmonary fibrosis in the EMPIRE registry. Eur. Respir. J. 2018;52:PA2203. doi: 10.1183/13993003.congress-2018.pa2203. DOI

Fukihara J., Kondoh Y., Brown K.K., Kimura T., Kataoka K., Matsuda T., Yamano Y., Suzuki A., Furukawa T., Sumikawa H., et al. Probable usual interstitial pneumonia pattern on chest CT: Is it sufficient for a diagnosis of idiopathic pulmonary fibrosis? Eur. Respir. J. 2020;55:1802465. doi: 10.1183/13993003.02465-2018. PubMed DOI

Hughes J.M.B., Pride N.B. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am. J. Respir. Crit. Care Med. 2012;186:132–139. doi: 10.1164/rccm.201112-2160CI. PubMed DOI

Goldin J., Cascella M. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2025. [(accessed on 17 August 2025)]. Diffusing Capacity of the Lungs for Carbon Monoxide. Available online: http://www.ncbi.nlm.nih.gov/books/NBK556149/ PubMed

Richeldi L., du Bois R.M., Raghu G., Azuma A., Brown K.K., Costabel U., Cottin V., Flaherty K.R., Hansell D.M., Inoue Y., et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New. Engl. J. Med. 2014;370:2071–2082. doi: 10.1056/NEJMoa1402584. PubMed DOI

Singer D., Bengtson L.G.S., Conoscenti C.S., Anderson A.J., Brekke L., Shetty S.S., de Andrade J. Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis. J. Med. Econ. 2022;25:532–540. doi: 10.1080/13696998.2022.2054203. PubMed DOI

Torrisi S.E., Pavone M., Vancheri A., Vancheri C. When to start and when to stop antifibrotic therapies. Eur. Respir. Rev. 2017;26:170053. doi: 10.1183/16000617.0053-2017. PubMed DOI PMC

Jovanovic D.M., Šterclová M., Mogulkoc N., Lewandowska K., Müller V., Hájková M., Studnicka M., Tekavec-Trkanjec J., Littnerová S., Vašáková M. Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: The EMPIRE registry study. Respir. Res. 2022;23:135. doi: 10.1186/s12931-022-02033-6. PubMed DOI PMC

Collum S.D., Amione-Guerra J., Cruz-Solbes A.S., DiFrancesco A., Hernandez A.M., Hanmandlu A., Youker K., Guha A., Karmouty-Quintana H. Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. Can. Respir. J. 2017;2017:1430350. doi: 10.1155/2017/1430350. PubMed DOI PMC

Rajagopal K., Bryant A.J., Sahay S., Wareing N., Zhou Y., Pandit L.M., Karmouty-Quintana H. Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. Br. J. Pharmacol. 2021;178:172–186. doi: 10.1111/bph.15036. PubMed DOI PMC